Summary
Background: Both patient survival and the proportion of patients diagnosed with thin cutaneous malignant melanoma (CMM) have been steadily rising in Sweden as in most western countries, though the rate of improvement in survival appears to have declined in Sweden at the end of last millennium.
Objectives: To analyse the most recent trends in the distribution of tumour thickness (Tcategory) as well as CMM-specific survival in Swedish patients diagnosed 1997-2011.
Methods: This nationwide population-based study included 30 590 patients registered in the Swedish Melanoma Register (SMR) and diagnosed with a first primary invasive CMM 1997-2011. The patients were followed through 2012 in the national Cause-ofDeath Register.
Results: Logistic and Cox regression analyses adjusting for age at diagnosis, tumour site, and health care region were carried out. The odds ratio for being diagnosed with thicker tumours was significantly reduced (P = 0·0008) and the CMM-specific survival 
Conclusion:
In Sweden, the CMMs of men are detected earlier over time and this seems to be followed by an improved CMM-specific survival for men. Women are still diagnosed with considerably thinner tumours and they experience a better survival than men.
Introduction
The incidence of cutaneous malignant melanoma (CMM) in Sweden has been steadily rising since 1958 when the Swedish National Cancer Register was started and made it possible to monitor all cancer. The annual percentage increase in the agestandardised incidence was almost 4% between the year 1999 and 2008 comparable to most western countries except Australia (1) .
In parallel to the increasing incidence of CMM there has been a rising proportion of patients diagnosed at an earlier T-category and the patient survival has improved considerably during the past decades in Sweden (2, 3), a trend that has also been observed in several other countries (4-7). In a recent report on patients diagnosed with CMM 1964-2003 in the Nordic countries, Swedish patients had the best survival, but the rate of improvement in survival tended to decline towards the end of period, especially among women (8) .
Tumour thickness is the strongest independent prognostic factor and is also the key variable in assessing early detection (6, 7) . A substantial increase in the proportion of T1 CMM for both men and women between 1976 and 1994 was previously described in a regional Swedish study (2) . Swedish national data have not yet been reported. The Swedish Melanoma Register (SMR) currently covers 98% of all cases of CMM reported to the Swedish National Cancer Register and since 1997 data on T-category have been almost complete.
The aim of this study was to analyse the recent trends in the distribution of tumour thickness (T-category) and CMM-specific survival in Sweden, by comparing patients diagnosed during consecutive 5-year periods: 1997-2001, 2002-2006, and 2007-2011, respectively, using data from the SMR.
Materials and methods

Data collection
Sweden, with about 10 million inhabitants, is divided into 6 health care regions. In each of these regions, regional melanoma groups exist with representatives in plastic and general surgery, dermatology, pathology, oncology, and the Regional Cancer Centre. The latter is responsible for cancer registration and coordination of regional cancer care. Since 1990 the Swedish Melanoma Study Group (SMSG), a multidisciplinary group with members from all health care regions, has prospectively gathered data concerning clinical characteristics, diagnosis, histopathology and primary treatment on all Swedish cases of CMM (comprehensively since 1996) (9) . Clinical data are collected by the reporting clinics and monitored/registered at the six Regional Cancer Centres in Sweden within a common data base, the SMR. Histopathological data for all patients are reported prospectively and electronically from the pathology departments into the population-based nationwide SMR. All cases are registered with a unique patient identity-number, which facilitates record linking to official death data (10) . SMR is thus a well-documented database with a high coverage. A first report based on SMR data in Sweden 1990-1999 has been published (9) . SMR data have recently been used in reports on the prognosis of T1 CMM (11), on level of education and survival (12) , and on cohabitation status and survival (13) .
During the time period 1997-2011, 31 098 patients with CMMs were reported to the SMR. From these, 508 patients (1·6%) with previous CMMs diagnosed before 1997 were excluded. Among the remaining 30 590 patients with first primary invasive CMM 828 (2·7%) lacked information on T-category. 6 The following variables from SMR were used in the present study: gender, age at diagnosis, date of diagnosis, tumour site, health care region, and T-category. Date and cause of death until December 31, 2012 were obtained from the Swedish Cause of Death Register.
Statistical analysis
All statistical analyses were performed for men and women separately. In all multivariate analyses, age was categorised into five groups (≤39, 40-54, 55-64, 65-79 and ≥80 years). In the age-specific analysis two groups were defined; <65 and ≥65 years. In all analyses, tumour thickness was analyzed as a categorical variable grouped according to the AJCC-2002 classification as T1 (≤1·0 mm), T2 (1·01-2·0 mm), T3 (2·01-4·0 mm) and T4 (>4·0 mm) (14).
Age-and gender-specific incidence rates per 100 000 inhabitants were calculated for each 5-year period of diagnosis.
To evaluate the association between period and T-category at diagnosis a multinomial logistic regression was used with T1 CMMs as reference. The results from the logistic regressions were expressed as odds ratios (OR) with 95% confidence intervals (CI). Proportional odds models were used in order to calculate P-values for OR trends over T-category. All logistic regression models also included age, tumour site, and health care region to adjust for any potential confounding effects of these variables.
Survival time was calculated from the date of diagnosis (date of diagnostic biopsy or date of pathology report) until date of the event or to the date of censoring. In the survival analyses, death from CMM was selected as the primary event. Censoring was made at the time point of: emigration, diagnosis of a second CMM (during the study period), death from causes other than CMM, or the cut-off date, December 31, 2012.
CMM-specific survival and CI were estimated using the method of Kaplan and Meier (15) . Cox's proportional hazard regression was used to assess the independent prognostic contribution of period of diagnosis after adjustment for the confounders' age and tumour site. The prognostic impacts were expressed as hazard ratios (HRs) with 95% CIs. Using stratified Cox regression models the analyses were adjusted for health care region. Patients with missing data on tumour site or T-category were excluded from the multivariable analyses. Statistical significance was indicated by P-values < 0·05. All statistical analyses were performed using SAS v9·3.
Results
Of the 30 590 patients diagnosed with a first primary invasive CMM between 1997 and 2011, 15 420 (50·4%) were women. During this period, men had a median age of Table 1 ).
The T-category distribution for the three periods is illustrated in Fig. 2 . In the logistic regression analysis after adjustments for age, tumour site and health care region, there was a statistically significant shift towards thinner tumours during 2007-2011 compared to 1997-2001 for men (P = 0·0008) but not for women (P = 0·28) ( Table 1 ). This trend towards thinner tumours was seen in both the younger (P = 0·02) and older (P = 0·01) In Cox regression analyses adjusted for age, tumour site and health care region, there were significant improvements in CMM-specific survival over time periods for men (P trend = 0·0009; Table 2 ). A 19% lower CMM death rate was found in men The corresponding change for women was 95·1 to 95·3% for younger women and 86·6 to 88·7% for older women ( Supplementary Fig. 1 ). CMM-specific survival per Tcategory showed a significant improvement for T3 CMM among men (69·2 to 72·6%, P trend = 0·026) and for T2 CMM among women (91·6 to 95·0%, P trend = 0·029) ( Supplementary Fig. 2 ).
Since there is a correlation between tumour thickness and the histogenetic type it is of interest to note that the proportion of nodular melanomas was lower in the period Table 2 ). Furthermore, among nonnodular melanoma the time trend in men towards a more favourable distribution on T category was still significant (Supplementary Tables 3 and 4) . Nodular melanomas showed an opposite trend becoming thicker in the last two time periods among both men and women (Supplementary Tables 5 and 6 ).
2007-2011 than in 1997-2001 (Supplementary
Discussion
In the present Swedish nationwide study including over 30 000 patients diagnosed with a first primary invasive CMM, the most important finding is a shift over time towards thinner tumours for men accompanied by an improved survival. This trend was seen in both younger and older men. The time trends of tumour thickness in CMM on a national level have not previously been studied in Sweden. A previous regional study based on data from 1976-1994 showed a pronounced increase of T1 CMM for both men and women (2) . In the present study, the proportion of T1 CMM among women was higher than for men but quite stable over time. In absolute terms, the proportion of T1 CMMs in women below 65 years was 8% higher than among men in the same age group. In addition, the proportion of T4 CMM was lower for women than for men in both age groups. These gender differences may partly be attributed to better skin selfexamination practices and health related behaviours in women resulting in thinner, potentially curable tumours. The improvement seen for men may have several reasons.
There have been no directed skin cancer awareness campaigns towards men in Sweden, instead one may speculate that men became more concerned with their health in general leading to change in their care seeking behaviour. Since the improvement towards a more favourable distribution of T category was seen also for older men one could speculate whether the increasing use of opportunistic prostate cancer screening by PSA testing might have had a similar positive effect on care-seeking behaviour among older men (via an elevated concern about their health). It has been estimated that at least onethird of all Swedish men aged 50-75 years had a PSA test between 2000 and 2007 (16) and this proportion has continued to increase.
The finding in the present study of a transient trend of thicker tumours in the middle period 2002-2006 is difficult to explain. While women appear to be more affected than men, the confidence intervals are overlapping so the sex difference may be due to chance. If so, one may speculate that the trend to some extent is associated with the changes in the Swedish health care system. In spite of an increasing population, the number of visits to physicians (including general practitioners) decreased slightly in the middle period but increased considerably in the last period. This study shows that women have a superior 5-year CMM-specific survival compared to men with 4·3% among patients aged below 65 years and 6·0% among patients aged 65 years or above. This difference is mainly due to behavioural factors with women diagnosed earlier and with a lower proportion of T3 and T4 CMM compared to men. Biological sex differences may also to some extent contribute to disparities in survival (25, 26). The 5-year CMM-specific survival in younger women is now above 95% leaving little room for further large improvements. Early detection measures directed to men and older women may improve their survival in a more substantial way. Low education and not living with a partner are other factors associated with a worse prognosis and those groups should be targeted for early detection efforts 13 (12, 13) . There are no data concerning the state of knowledge regarding CMM in the general population. The knowledge in Swedish CMM patients about the importance of early detection is in general comparably good and the media seems to be the most important source of information (27).
In conclusion, the CMMs of men are detected earlier over time and this seems to be followed by an improved CMM-specific survival for men. Women are still diagnosed with considerably thinner tumours and they experience a better survival than men. 
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